Carter J. Barger

Keywords TERT promoter mutation telomere tumor immortality pan-cancer noncoding mutation GABP Introduction Tumor cells can achieve replicative immortality through reactivation of telomerase reverse transcriptase (TERT).1,2,3,4,5,6,7,8,9,10,11,12,13 A heterozygous point mutation in the TERT promoter reactivates TERT expression to overcome the strict limits on cellular lifespan.7,9 In the absence of TERT activation, activated oncogenes drive cells into senescence or death instead of producing...

This study complies with all relevant ethical regulations and was approved by the Committee on Human Research of the University of California, San Francisco. All patients provided informed written consent prior to sample acquisition. Patients were not monetarily compensated. AACR project GENIE dataset The tenth dataset of AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE), Cohort v10.0-public, was accessed from cBioPortal and queried for TERT promoter mutations25.

Abstract The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that FOXM1 is co-amplified and co-expressed with RHNO1, a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress (RS) response.